GlaxoSmithKline is asking the U.S. Supreme Court to upend a Third Circuit ruling in a case over the marketing of the diabetes medication Avandia, saying the appeals court had taken an “impossibly capricious view” of the drug company’s duty to provide information to regulators…

Read this piece in its entirety at Law360.